TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05192941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Subcutaneously injected on Day 1, Day 90, and Day 270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to inclisiran 300 mg subcutaneously
Study: NCT05945264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Intervention (MI)
Description: The intervention will involve listening, playing and/or singing melodies or songs, that are meaningful to the participant, with interpretation/reflection on their relevance/capacity to alter stress.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control (SC)
Description: The intervention will be to support a woman to talk about anything she wants that is important to her.
Study: NCT04899336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC9V
Description: ExPEC9V will be administered as an IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as an IM injection.
Study: NCT06576115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic P1
Description: This treatment consists of delivering preset low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
Study: NCT06282809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
Description: Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
Study: NCT06341621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-year abemaciclib without chemo
Description: aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment of physician's choice
Description: treatment of physician's choice including whether to receive chemotherapy, chemotherapy regimen and endocrine therapy regimen.
Study: NCT06407076

Intervention type: OTHER
Intervention: Interviews
Description: Following the design of the questionnaire, using open-ended questions based on the availability, accessibility, acceptability and quality (AAAQ) framework, qualitative semi-structured personal interviews were used to collect the data. In this way it was possible to collect information in a more detailed way. The subjects included in the study had to answer the questions posed by the main researcher, responding with open or closed answers, through a questionnaire created for this purpose.
Study: NCT05608304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal mindfulness induction
Description: The formal mindfulness induction will consist of a 10-minute audio recording of a sitting meditation, guiding the participant to consciously and repeatedly bring their attention to their breath and inner experience with nonjudgmental acceptance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informal mindfulness induction
Description: The informal mindfulness induction will consist of on-screen instructions guiding participants through the completion of four routine tasks (washing hands, drinking water, laying down, listening to music) with mindful awareness and acceptance over the course of 10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control task
Description: Participants assigned to the active control condition will be prompted to download a single-page document containing 100 letters, numbers, and symbols, and a grid of 100 boxes. Following along with a guided audio, participants will be instructed to place all of the characters in the grid in a specific order over the course of 10 minutes. A version of this task has been used in previous studies by our team (Carsley \& Heath, 2019; Petrovic et al., 2022) and has been shown not to impact mindfulness levels, and was thus deemed an appropriate neutral attention task for this study.
Study: NCT05834972

Intervention type: DEVICE
Intervention: Ultrasound-guided percutaneous dilatational tracheosyomy
Description: All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
Study: NCT04999644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Nicotine Cigarettes
Description: A full nicotine tobacco cigarette that will be smoked by participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full Nicotine Cigarettes
Description: A full nicotine tobacco cigarette that will be smoked by participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Cigarettes
Description: A reduced nicotine tobacco cigarette that will be smoked by participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Cigarettes
Description: A reduced nicotine tobacco cigarette that will be smoked by participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average Nicotine Expectancy
Description: Participant instructed the cigarette is the same level of nicotine as your usual brand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Average Nicotine Expectancy
Description: Participant instructed the cigarette is the same level of nicotine as your usual brand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Expectancy
Description: Participant instructed the cigarette is a very low level of nicotine compared to your usual brand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Expectancy
Description: Participant instructed the cigarette is a very low level of nicotine compared to your usual brand.
Study: NCT06645860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF+KI+LED Light 20s
Description: After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SDF+KI
Description: Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDF+KI
Description: Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
Study: NCT06645730

Intervention type: DIAGNOSTIC_TEST
Intervention: hypertension
Description: diagnosed with hypertension

Intervention type: DIAGNOSTIC_TEST
Intervention: diabetes
Description: diagnosed with diabetes

Intervention type: DIAGNOSTIC_TEST
Intervention: fatty liver
Description: diagnosed with fatty liver on CT
Study: NCT06645548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight estimation using 3D camera
Description: Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
Study: NCT05797116

Intervention type: OTHER
Intervention: Survey
Description: 29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
Study: NCT06243185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus letrozole
Description: Dalpiciclib 150mg qd, d1-21, repeated once every 4 weeks. Letrozole 2.5mg qd, repeated once every 4 weeks.
Study: NCT06382714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: For the intervention group, a museum visit with virtual reality glasses will be applied.
Description: Patients will visit a museum while undergoing hemodialysis with virtual reality glasses for a total of five sessions for intervention group
Study: NCT06504667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Mini
Description: The Point Mini finger prosthetic system consists of 1-4 ratcheting mechanical digits and mounting brackets
Study: NCT05884463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPI
Description: Intravenous injection of one dosage of 18F-FAPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of one dosage of 18F-FDG.
Study: NCT05788835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE and HAIC
Description: Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion
Study: NCT04783441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: access to continuous glucose monitoring in the Dexcom G6 arm 24/7

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dexcom G6 blinded sensor
Description: retrospective access to continuous glucose profile after 10 days of wear
Study: NCT05788835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE
Description: Drug-eluting bead transarterial chemoembolization
Study: NCT01874314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: 300mg or 450mg of SQ109 administered orally, once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: 300mg or 450mg of SQ109 administered orally, once daily for 7 days.
Study: NCT05561907

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical gastrojejunostomy (SGJ)
Description: Laparoscopic gastrojejunostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastrojejunostomy (EGJ)
Description: Endoscopic ultrasound (EUS) guided gastrojejunostomy
Study: NCT05450354

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires will be completed only once :~* Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~* Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~* Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~* Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects.

Intervention type: OTHER
Intervention: Questionnaire
Description: Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
Study: NCT01874314

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SQ109 Placebo
Description: Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
Study: NCT05450354

Intervention type: OTHER
Intervention: Questionnaire
Description: Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
Study: NCT04946929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet [Brilinta]
Description: Ticagrelor, 2-3mg/kg, 12h, p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low molecular weight heparin
Description: half amount low molecular weight heparin
Study: NCT06300138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared thermotherapy apparatus
Description: infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Itraconazole and Infrared thermotherapy apparatus
Description: oral itraconazole (children less than 15 years old 6 mg/kg/d; adult patients: 200 mg/d) for a total course of 3-6 months, while infrared hyperthermia device for 3 consecutive days (times / day), each treatment for 30 minutes After two weeks (14 days), the lesions of the same target were treated continuously for 2 days (times per day), and then once a week for 2 consecutive times, the method was the same as before. After 7 times of treatment, the study physician decided whether to continue treatment n times after 1-2 weeks (n ≥ 0) according to the recovery of the subjects.
Study: NCT05265455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols 2.5 g/day
Description: Daily consumption of one stick (2.5 g of plant sterols) during lunch or dinner for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily consumption of one stick (the same matrix without plant sterols) during lunch or dinner for 3 weeks
Study: NCT05673876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-8264
Description: GDC-8264 tablets will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-8264
Description: GDC-8264 tablets will be administered as per the schedule specified in the respective arms.
Study: NCT05917301

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation
Description: This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.
Study: NCT05663515

Intervention type: DRUG
Intervention: Exenatide
Description: All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.

Intervention type: DRUG
Intervention: Non-GLP-1 RA based glucose lowering drugs
Description: Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
Study: NCT05944055

Intervention type: BIOLOGICAL
Intervention: Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?
Description: Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.

Intervention type: BIOLOGICAL
Intervention: Is 25 OH vitamin D overdose a risk factor of bronchopulmonary dysplasia or death ?
Description: Vitamin D overdose is frequent among preterm infants receiving the current supplementation (Mauras 2022, Kołodziejczyk-Nowotarska 2021). In our NICU, the protocol was to daily administrate 55 UI vitamin D during parenteral nutrition then 1000 UI during enteral nutrition for babies weighing more than 1000 g and 1200UI during enteral nutrition for babies weighing less than 1000 g. The dosage was adapted each month after a plasmatic measure of 25OH-D in order to maintain 25OH-D between 50 nmol/L and 120 nmol/L.
Study: NCT06623396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M28z1XXPD1DNR CAR
Description: Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
Study: NCT06624527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation based on Cognitive Behavioral Therapy
Description: A psycho-educational application based on Cognitive Behavior Therapy consisting of a total of 8 sessions prepared by the researcher.
Study: NCT06686745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0508 Tablets
Description: Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0508 in combination with olaparib
Description: Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0508 in combination with olaparib
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
Study: NCT06748989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cortexium food supplement
Description: Cortexium (a specially formulated dietary supplement with pyrroloquinoline quinone, γ-aminobutyric acid and B vitamins).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo food supplement
Description: Placebo food supplement is completely identical weight and outlook capsule to Cortexium, with 50% microcrystalline cellulose and 50% starch.
Study: NCT06752148

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: neurofeedback intervention training game
Description: 1. Issuance of training equipment and training in its use: For subjects randomly assigned to the intervention group, a volunteer who has received adequate training in the use of the equipment will issue the EEG monitoring electrodes (model: HXD-1) and paired PADs, and will provide an activated account for the use of the subject only and training in its use. Subjects will be provided with a short tutorial on how to use the APP, which is very user-friendly and suitable for elderly novices. An initial training session will consist of 3 training components and will be completed with a volunteer.~2. Training programme and supervision: The closed-loop neurofeedback training will consist of 3 parts, namely Digital Meditation, Brain Training and Sleep Induction. The brain training will consist of three games: Idea Chase, Idea Magic Ball and Focused Archery. The control subjects lived a normal life before the surgery, and all subjects underwent the surgery as planned.
Study: NCT06763952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-BRIDGE
Description: AI-based eye screening program
Study: NCT06763276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Group
Description: In the study, a 400-gram virtual reality (VR) headset with an anti-reflective lens system was used, compatible with all earphones with screens ranging from 4.5 to 7.0 inches. The virtual reality (VR) headset, which was lightweight enough for children to wear, was supported on three sides to fit securely on the children's heads and was disinfected after each use. For the experimental group, the compartment at the front of the virtual reality (VR) headset was removed. The earphone was placed into the removed compartment, which was then reinserted. Subsequently, the YouTube virtual reality (VR) feature was activated on the phone, making it ready for viewing.
Study: NCT06763731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane COMPLETE
Description: Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
Study: NCT04971785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (SEMA)
Description: Administered as subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (SEMA)
Description: Administered as subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor (CILO)/Firsocostat (FIR)
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor (CILO)/Firsocostat (FIR)
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM SEMA
Description: Administered as SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM SEMA
Description: Administered as SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTM CILO/FIR
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM CILO/FIR
Description: Tablets administered orally
Study: NCT02379377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative 18F-FSPG
Description: Undergo 18F-FSPG PET scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative 18F-FSPG
Description: Undergo 18F-FSPG PET scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carbon C 11 Acetate
Description: Undergo 11C-acetate PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose
Description: Undergo 18F-FDG PET scan
Study: NCT06604143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality Training
Description: Participants will engage in piano playing tasks using their affected hand and fingers. The training focuses on specific aspects of finger movement, and participants will receive feedback related to their playing. They will wear a wrist brace for support, and their hand and arm positions will be monitored to ensure proper technique.